Comment from Wave Life Sciences

Summary: Wave Life Sciences, a biotechnology company, supports the draft guidance on New Approach Methodologies (NAMs) and advocates for its expansion to include specific considerations for oligonucleotide therapeutics. They suggest harmonizing NAM validation across different FDA centers, clarifying the distinction between qualification and validation, and providing more specific guidance on translating in vitro metrics to in vivo exposure.